Breaking News Instant updates and real-time market news.

RXDX

Ignyta

$5.56

-0.04 (-0.71%)

10:45
10/17/16
10/17
10:45
10/17/16
10:45

Ignyta has a conference call hosted by JPMorgan

JPMorgan Analysts Kasimov, Fye and Rama will host a conference call with CEO Jonathan Lim and CFO Jacob Chacko on October 17 at 11 am.

  • 17

    Oct

  • 06

    Nov

  • 29

    Nov

RXDX Ignyta
$5.56

-0.04 (-0.71%)

06/23/16
JPMS
06/23/16
INITIATION
Target $15
JPMS
Overweight
Ignyta initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Ignyta with an Overweight rating and $15 price target, saying the company's lead program entrectinib is underappreciated from both a clinical and commercial perspective. Rama also views taladegib and RXDX-105 as interesting assets and potential long-term value drivers, though they are not currently included in the valuation model used to arrive at the $15 target.
05/11/16
PIPR
05/11/16
NO CHANGE
Target $32
PIPR
Overweight
Piper still surprised by Ignyta's 'modest valuation'
Piper Jaffray analyst Joshua Schimmer says he remains surprised by Ignyta's "modest valuation" given the company's "multiple attractive assets." Ignyta reported Q1 results last night provided some useful updates on entrectinib and taladegib, Schimmer tells investors in a research note. He keeps an Overweight rating on the shares with a $32 price target.
04/18/16
LEER
04/18/16
NO CHANGE
LEER
Outperform
Ignyta entrectinib continues to show 'encouraging' efficacy, says Leerink
Leerink analyst Paul Matteis says Ignyta's (RXDX) entrectinib continues to show "encouraging" efficacy and safety in an expanding sample of treated patients, following updated Phase 1 data presented by the company. The analyst says entrectinib shows "strong efficacy" in ROS1 with an 86% response rate, an 85% response rate in non-small cell lung cancer and multiple responses past 18 months. Loxo Oncology's (LOXO) LOXO-101, a competing inhibitor, also showed "nice efficacy data" with a comparable response rate, Matteis tells investors in a research note. The analyst reiterates an Outperform rating on Ignyta's shares.
04/18/16
PIPR
04/18/16
NO CHANGE
Target $32
PIPR
Overweight
Ignyta remains a top pick at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Ignyta (RXDX) remains a top pick after the company over the weekend reported additional data from the ongoing entrectinib Phase 1 ALKA and STARTRK studies. The data continue to highlight the clinical activity in solid tumors as well as a generally tolerable profile, Schimmer tells investors in a research note. Loxo Oncology (LOXO) also reported Phase 1 data for an NTRK inhibitor, and the two drugs "appear fairly similar," the analyst contends. Schimmer believes this should help drive positive sentiment for Ignyta since there was investor concern that the Loxo data would appear superior. He keeps an Overweight rating on Ignyta with a $32 price target.

TODAY'S FREE FLY STORIES

08:40
06/29/17
06/29
08:40
06/29/17
08:40
General news
U.S. initial jobless claims rose 2k to 244k in the week ended June 24 »

U.S. initial jobless…

AMRN

Amarin

$3.78

0.29 (8.31%)

08:39
06/29/17
06/29
08:39
06/29/17
08:39
Recommendations
Amarin analyst commentary  »

Jefferies boosts Amarin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$32.81

0.65 (2.02%)

08:39
06/29/17
06/29
08:39
06/29/17
08:39
Hot Stocks
Celltrion, Teva announce FDA acceptance of BLA for Rituxan biosimilar »

Celltrion and Teva…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

IMNP

Immune Pharmaceuticals

$2.97

0.15 (5.32%)

08:38
06/29/17
06/29
08:38
06/29/17
08:38
Hot Stocks
Immune Pharmaceuticals reaches agreement on Pint Pharma transaction »

Immune…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKBA

Akebia

$15.50

-0.19 (-1.21%)

08:38
06/29/17
06/29
08:38
06/29/17
08:38
Technical Analysis
Technical View: Akebia falls on 4M share Spot Secondary »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

PIR

Pier 1 Imports

$5.38

0.04 (0.75%)

08:38
06/29/17
06/29
08:38
06/29/17
08:38
Downgrade
Pier 1 Imports rating change  »

Pier 1 Imports downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTLS

Chart Industries

$33.15

0.91 (2.82%)

08:37
06/29/17
06/29
08:37
06/29/17
08:37
Upgrade
Chart Industries rating change  »

Chart Industries upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Wal-Mart

$76.51

0.5 (0.66%)

, AMZN

Amazon.com

$990.33

13.55 (1.39%)

08:37
06/29/17
06/29
08:37
06/29/17
08:37
Periodicals
Walmart sending 'veiled' threats to truckers amid war with Amazon, NY Post says »

Walmart (WMT) is sending…

WMT

Wal-Mart

$76.51

0.5 (0.66%)

AMZN

Amazon.com

$990.33

13.55 (1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNI

Silver Spring

$11.28

0.1 (0.89%)

08:36
06/29/17
06/29
08:36
06/29/17
08:36
Hot Stocks
Silver Spring selected for Grant PUD advanced metering program »

Silver Spring Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPNC

Spectranetics

$38.35

7.95 (26.15%)

08:36
06/29/17
06/29
08:36
06/29/17
08:36
Downgrade
Spectranetics rating change  »

Spectranetics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNA

Arena Pharmaceuticals

$16.53

1.3 (8.54%)

08:35
06/29/17
06/29
08:35
06/29/17
08:35
Hot Stocks
Arena Pharmaceuticals completes ralinepag Phase 1 trial »

Arena Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

CCJ

Cameco

$9.53

0.1056 (1.12%)

08:35
06/29/17
06/29
08:35
06/29/17
08:35
Initiation
Cameco initiated  »

Cameco initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUBN

Commerce Union Bancshares

$26.04

1.54 (6.29%)

08:34
06/29/17
06/29
08:34
06/29/17
08:34
Hot Stocks
Commerce Union Bancshares raises quarterly dividend 9.1% to 6c per share »

Commerce Union Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

PFE

Pfizer

$33.75

-0.02 (-0.06%)

08:33
06/29/17
06/29
08:33
06/29/17
08:33
Hot Stocks
Pfizer to evaluate Alcyone's Pulsar technology to develop genetic therapy method »

Pfizer has entered into a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jul

  • 02

    Aug

  • 27

    Aug

08:32
06/29/17
06/29
08:32
06/29/17
08:32
General news
Jobless Claims data reported »

Week of 6/24 Jobless…

08:32
06/29/17
06/29
08:32
06/29/17
08:32
General news
Real GDP data reported »

Real GDP up 1.4% vs.…

INPX

Inpixon

08:32
06/29/17
06/29
08:32
06/29/17
08:32
Syndicate
Inpixon raises $6M in a public offering of common stock and warrants »

Inpixon announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OA

Orbital ATK

$98.71

1.7 (1.75%)

08:32
06/29/17
06/29
08:32
06/29/17
08:32
Hot Stocks
Orbital ARK receives contract to repair trainer aircraft for Iraqi Air Force »

Orbital ATK has received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CST

CST Brands

, LBIO

Lion Biotechnologies

08:30
06/29/17
06/29
08:30
06/29/17
08:30
Options
One new option listing and two option delistings on June 29th »

New option listings for…

CST

CST Brands

LBIO

Lion Biotechnologies

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$154.30

0.58 (0.38%)

08:26
06/29/17
06/29
08:26
06/29/17
08:26
Recommendations
McDonald's analyst commentary  »

McDonald's price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$27.08

-0.13 (-0.48%)

08:22
06/29/17
06/29
08:22
06/29/17
08:22
Upgrade
General Electric rating change  »

General Electric upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

$DJT

DJ Transportation Average

08:21
06/29/17
06/29
08:21
06/29/17
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

08:20
06/29/17
06/29
08:20
06/29/17
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

08:20
06/29/17
06/29
08:20
06/29/17
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$28.35

1.05 (3.85%)

08:20
06/29/17
06/29
08:20
06/29/17
08:20
Recommendations
Trinity Industries analyst commentary  »

Trinity Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.